Pharma: Other News To Note
Wednesday, July 18, 2012
Janssen Biotech Inc., of Horsham, Pa., a unit of Johnson & Johnson, said it submitted a supplemental biologics license application to the FDA and a Type II Variation to the European Medicines Agency requesting approval of Simponi (golimumab) in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.